The U.S. Food and Drug Administration (USFDA) has concluded a GMP inspection of Biocon’s API facility (Site 5), located at Visakhapatnam, Andhra Pradesh, on June 21, 2024. Four observations were cited at the end of the Inspection, which the company will be addressing within the stipulated time.
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.